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Commentary
A central paradox of controlling coagulation in the
patient undergoing thoracotomy and cardiopulmonary
bypass (CPB) emerges as the cardiac surgeon strives to
achieve blood fluidity within the CPB circuit and the
patient’s vasculature, as well as an effective procoagu-
lant response to ensure protective hemostasis in the
wound (Fig 1). Heparin, the gold standard for CPB,
inhibits the coagulation mechanism at multiple levels,
especially in the final common pathway, thereby block-
ing in parallel the intravascular and extravascular pro-
coagulant responses. However, the properties of
heparin allowing it to so effectively target the final
common pathway of coagulation underlie its potential
causation of excessive bleeding in hemostatically com-
promised patients.
The properties of thrombin emphasize the biologic
complexity and dichotomous nature of the coagulation
mechanism when it is integrated into the context of host
response effector mechanisms. Thrombin activates cel-
lular elements through cleavage of protease-activated
receptors; short-term consequences of this mechanism
include activation of platelets, and longer-term implica-
tions of protease-activated receptor stimulation may
include changes in vascular smooth muscle cell proper-
ties underlying restenotic and other vascular lesions.1
As a procoagulant enzyme per se, thrombin magnifies
and modulates its biologic effects in a dichotomous
fashion; thrombin activation of factor XI provides a pos-
itive feedback mechanism reinforcing the generation of
procoagulants through the intrinsic system.2 Thrombin
also stimulates the thrombin activatable fibrinolysis
inhibitor, thus diminishing the efficacy of clot lysis.3
In contrast to the above procoagulant effects of
thrombin, after binding to the endothelial cofactor
thrombomodulin, this enzyme also cleaves the plasma
zymogen protein C, resulting in formation of activated
protein C (APC).4 APC is the key enzyme in the
endogenous antithrombotic protein C–protein S (the
latter a cofactor for APC) mechanism, which damps
the final common pathway by proteolytically inacti-
vating factors Va and VIIIa. APC also appears to have
other vasculoprotective effects resulting from its inter-
action with plasminogen activator inhibitor-1 and by
mechanisms yet to be fully characterized. In the latter
context, APC affords protection against a lethal dose
of intravenous Escherichia coli, and, in models of
myocardial ischemia, APC appears to limit tissue
injury by effects that may extend beyond its coagulant
properties.4 The importance of the protein C–protein S
pathway as a natural anticoagulant mechanism is
emphasized by the prothrombotic diathesis observed
in patients with significant functional deficiency of
either plasma protein.4
On the basis of this discussion, formation of APC is
expected when thrombin is generated. In the current
issue of the Journal (see page 422), Petäjä and col-
leagues report that APC is generated during CPB and
coronary reperfusion. Enhanced APC formation during
the immediate reperfusion period is not unexpected.
Restoration of blood flow delivers both key substrates
for energetic metabolism and effector mechanisms
capable of inflicting vascular damage, such as polymor-
phonuclear leukocytes, complement, and coagulation
components to systemic cardiac vasculature. The net
result is increased generation of thrombin, causing both
cleavage of fibrinogen with release of fibrinopeptide A
(Fig 2 in Petäjä and colleagues) and increased APC for-
mation (Fig 1, C and D in Petäjä and colleagues).
Furthermore, that patients who demonstrate more
robust formation of APC (“good responders”) are those
with enhanced hemodynamic performance (Fig 3 in
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Petäjä and colleagues) is also not unexpected because
effective reperfusion will generate both a procoagulant
(production of fibrinopeptide A) and anticoagulant (pro-
duction of APC) response. However, there is the intrigu-
ing possibility that APC may be doing more than sim-
ply reflecting hemodynamic status, based on its
vasculoprotective effect in animal models of ischemia.
This is an area for future study that may reveal yet
another example of the interdependence of the coagula-
tion mechanism and cardiovascular function.
How can we integrate these findings into a broader
understanding of the role of the coagulation mecha-
nism in CPB procedures?
1. Local (wound) and CPB-induced activation of
coagulation during thoracotomy/CPB trigger is un-
avoidable (thus anticoagulant therapy is required) and
is integral to the protective response mounted to inva-
sion of the extravascular and intravascular spaces. An
important component of this procoagulant response is
the triggering of endogenous antithrombotic mecha-
nisms, such as activation of formation of APC. Thus
more selective antithrombotic therapy administered to
patients during CPB/reperfusion, with the goal of spar-
ing natural anticoagulant mechanisms, might be
expected to buttress vascular protective pathways.
2. Nonspecific inhibition of the coagulation mecha-
nism by an agent such as heparin is also more likely to
damp natural antithrombotic mechanisms tied to the
Fig 1. Schematic depiction of the procoagulant response to thoracotomy/cardiopulmonary bypass (CPB). TAFI,
Thrombin-activatable fibrinolysis inhibitor; APC, activated protein C; TF, tissue factor.
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procoagulant pathway, such as the protein C–protein S
mechanism.
3. From a general perspective of prothrombotic
mechanisms operative in thoracotomy/CPB (Fig 1),
more selective control of coagulation might be
achieved by damping effects of the intrinsic system
without critically interfering with extravascular clot-
ting. In this regard, targeting factor IX/IXa would
inhibit both activation of the intrinsic system by the
CPB tubing, as well as tissue factor–dependent, mono-
cyte-mediated mechanisms in the CPB circuit (where
low levels of tissue factor favor activation of factor IX
over that of factor X)5 and has been shown to be effec-
tive in canine and baboon models.6,7 Such a selective
anticoagulant approach would be expected to more
minimally affect the generation of natural antithrom-
botics, such as the protein C pathway.
The coagulation pathway is an integral part of the
host response to surgical procedures, and events that
begin as an apparently simple response to stem local
blood loss can actually have wide-ranging implications
as locally formed thrombin modulates cellular proper-
ties (including direct effects on the vasculature), acti-
vates protein C, and exerts a range of other effects as
well. Selective damping of the procoagulant mecha-
nism to limit intravascular coagulation during surgery
will undoubtedly be the future direction of anticoagu-
lant therapy. The goal of such therapy will be to main-
tain extravascular hemostasis and allow natural
antithrombotic mechanisms, such as formation of APC,
to occur with minimum inhibition while preventing
thrombosis in the CPB circuit and vasculature.
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